At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 328 enrolled
Drug / intervention
OnabotulinumtoxinA X +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Double-Blind, Randomized, Placebo-Controlled Parallel-Group Phase 2 Study Evaluating the Safety and Efficacy of OnabotulinumtoxinA X for the Treatment of Moderate to Severe Glabellar Lines
In Brief
A Phase 2 clinical trial evaluating OnabotulinumtoxinA X and Placebo for Glabellar Lines. Completed, enrolled 328 participants across 18 sites.
Detailed Summary
This is a Phase 2, dose ranging study to evaluate the safety of OnabotulinumtoxinA X and to compare the efficacy of OnabotulinumtoxinA X and placebo for the treatment of Glabellar Lines in adult participants with moderate to severe GL.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlabellar Lines
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20222023202420252026
Enrollment StartOct 2021
First PostedOct 2021
Primary CompletionDec 2022
TodayJul 2026
First PostedOct 29, 2021
Enrollment StartOct 6, 2021
Primary CompletionDec 2, 2022
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 4.7 years ago
Interventions
OnabotulinumtoxinA Xdrug
Injection
Placebodrug
Injection